Table 3.

Risk Factor Analysis for Noninfectious Interstitial Pneumonia

Factors		Univariate Analysis			Multivariate Analysis
		HR	95% CI	P Value	HR	95% CI	P Value
Age, y	≥50	1.20	1.03–1.39	.017	1.06	0.79–1.42	.71
Disease	AML	1.00		.003a	1.00		.004a
	ALL	0.78	0.63–0.96	.020	.68	0.49–0.94	.031
	MDS	1.04	0.83–1.29	.76	1.06	0.79–1.42	.71
	ML	1.23	1.02–1.49	.035	1.30	1.004–1.69	.047
Donor	MRD	1.00		<.001a	1.00		.19a
	MMRD	0.67	0.51–0.90	.007	.72	0.48–1.08	.11
	MUD	0.83	0.64–1.07	.15	.95	0.67–1.35	.77
	MMUD	0.88	0.66–1.16	.36	.86	0.59–1.28	.46
	CB	1.13	0.92–1.40	.26	1.08	0.79–1.48	.64
Conditioning	RIC	1.01	0.87–1.18	.91	1.07	0.82–1.38	.64
TBI	>8 Gy	1.01	0.86–1.19	.91	1.57	1.18–2.10	.002
HCT-CI minus pulmonary component	≥1	1.13	0.97–1.31	.13	.96	0.77–1.19	.72
Pulmonary comorbidity	Yes	1.43	1.21–1.70	<.001	1.24	0.97–1.59	.082
Platelet engraftmentb	…	0.48	0.40–0.58	<.001	.58	0.45–0.75	<.001
aGVHD3–4b	…	1.01	0.81–1.26	.94	.98	0.74–1.31	.91
Candidemiab	…	2.60	1.77–3.82	<.001	2.51	1.48–4.25	<.001
Bacteremiab	…	1.20	1.01–1.42	.036	.94	0.74–1.20	.62
CMV reactivationb	…	1.26	0.91–1.73	.16	1.29	0.93–1.79	.13

Abbreviations: aGVHD3–4, grade III-IV acute graft-vs-host disease; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CB, cord blood; CMV, cytomegalovirus; HCT-CI, hematopoietic cell transplantation-specific comorbidity index; HR, hazard ratio; MDS, myelodysplastic syndrome; ML, malignant lymphoma; MMRD, HLA-mismatched related donor; MMUD, HLA-mismatched unrelated donor; MRD, HLA-matched related donor; MUD, HLA-matched unrelated donor; RIC, reduced-intensity conditioning; TBI, total body irradiation.

^aOverall comparison.

^bTime-dependent covariate.